Update on Dolutegravir for children;
Isoniazid preventive therapy in pregnancy: update
The importance of the gut microbiota to health in HIV; Update on risk for neural tube disorders for women on dolutegravir at conception: downgraded but real risk; No clinically significant interaction between dolutegravir and valproate
Tuberculosis Preventive Therapy for Adults; Undetectable = Untransmittable (U=U); Important drug-drug interactions with dolutegravir
Potential safety issue affecting HIV+ women taking dolutegravir at the time of conception; New WHO guidelines for induction therapy in cryptococcal meningitis; Treatment of cytomegalovirus (CMV) retinitis; Isoniazid preventive therapy (IPT) in pregnancy
Dolutegravir in pregnancy; Is there still a role for nevirapine?; The Xpert MTB/RIF Ultra: increased sensitivity for diagnosing HIV-associated TB with a small increase in false positive results; Treatment of multi-drug resistant gonorrhoea - what's in the pipeline?
Severe efavirenz-induced ataxia and encephalopathy; Prolonged post-treatment virologic control in a South African HIV+ child after early antiretroviral therapy; The DAWNING trial.
Early ART initiation as a factor in combating antibiotic resistance; Dolutegravir: not as monotherapy;
BREATHER - Can HIV+ youth safely have a weekend off their antiretroviral medication?; Diagnosing "elite controllers"
Rifabutin dosing with protease inhibitors; Drug-drug interactions involving second generation NNRTIs; Pure Red Cell Aplasia in HIV
Dolutegravir: its use in adult patients
Dolutegravir: its use in paediatric patients
Drug-drug interactions between antiretrovirals and itraconazole
Zika and HIV
Do elite controllers need ART?
Early infant diagnosis of HIV - shifting paradigms
Lifelong ART should be offered to ALL HIV-infected patients regardless of CD4 count
Pneumococcal vaccination in HIV-infected persons
Probiotics and HIV
Improved treatment outcomes in patients with XDR TB in South Africa
HIV tests in children on ART
Management of hyperlipidaemia in patients on protease inhibitors
Cross-reactivity between darunavir and co-trimoxazole
New 0199 tariff claiming process
Rilpivirine (RPV) in pregnancy
Is there a need for 6-monthly CD4 monitoring in patients with stable virological suppression on ART?
Twitter for the busy Clinician - Opening up a world of HIV-related information
The role of micronutrient supplementation in adults
HIV-positive-to-HIV-positive renal transplantation
Pre-exposure prophylaxis (PrEP): recent findings add to the evidence that it is effective as an HIV prevention tool
Use of raltegravir in children
Balancing risks and benefits in post exposure prophylaxis
Abacavir-based regimens in patients with high viral loads
Proton pump inhibitor, H2 receptor blocker and antacid drug interactions with atazanavir/ritonavir
Update on the Mississippi child - a reality check
Maraviroc
A festive reflection
The EARNEST trial: new evidence regarding efficacy of second line ART regimens
New drug profile: rilpivirine
The value of a psychological report in treatment failure
Clinical Case Report - 35 year old male patient on a PMB Medical Scheme Option (Subject to State Protocols)
Monkeypox crisis UK; Conference reports; ARVs, Paediatric care
This issue of HTB includes several articles on different aspects of the current monkeypox (MPX) outbreak.
Conference reports; ARVs; Complications: Covid-19; HIV prevention
Donating meds to Ukraine and further reports from CROI 2022
Ukraine invaded, links to donate, 17 CROI 2022 reports…
HTB Jan/Feb with rapid reports from CROI 2022…
New on new HIV and COVID drugs – and need for third vaccines…
Weight gain and weight loss, BHIVA, COVID-19 and vaccine efficacy at low CD4 counts…
Antiretroviral treatment optimisation
November / December 2017 - HTB
September / October 2017 - HTB
January / February 2017 - HTB
November / December 2016 - HTB
This booklet now focuses as much on getting the best quality of life as it does on side effects.
This booklet is a guide for anyone interested in HIV treatment. It is especially for HIV positive people to feel more in control of this part of life. The guide was written and reviewed by HIV positive people, activists and health professionals. Information is based on the 2016 update to the UK guidelines and the pill chart include all newly approved drugs.
September / October 2016 - HTB
January / February 2016 - HTB
November / December 2015 - HTB
September / October 2015 - HTB
January / February 2015 - HTB
The 2014 Pipeline report, co-authored by i-base and TAG, covers HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure and immune-based and gene therapies in development
The 2013 Pipeline report, co-authored by HIV i-base and TAG, covers HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure and immune-based and gene therapies in development
The annual i-Base/TAG pipeline report, which covers research into drugs and diagnostic tests that are the most advanced in development
HTB South: Conference coverage includes a meeting on HIV and women’s health, another on HIV persistence and cure research, as well as the European AIDS Conference and ICAAC.
HTB South: Includes final reports from IAS 2011 looking at the latest in cure research, ART and TB, and reassuring circumcision results from Orange Farm that dispel concerns about risk compensation.
HTB South: This issue leads with the most important and exciting research from the IAS conference in Rome and the 3rd International Workshop on HIV Pediatrics immediately preceding it.
HTB South: 1st International Workshop on HIV and Women
HTB South: 16th Conference on Retroviruses and Opportunistic Infections
HTB South: 17th Conference on Retroviruses and Opportunistic Infections (CROI)
HTB South: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV (IWADR)
HTB South: i-Base Q&A: swine flu and HIV
HTB South: 16th Conference on Retroviruses and Opportunistic Infections (CROI)
HTB South: 16th Conference on Retroviruses and Opportunistic Infections
HTB South: OCTANE Trial DSMB finds ritonavirboosted lopinavir superior to nevirapine in HIV-positive women previously exposed to single dose nevirapine
HTB South: 38th World Conference on Lung Health of the Union against TB and Lung Disease
